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1. Introduction 
Type B insulin resistance is a rare syndrome caused by anti-insulin receptor antibody. The 
anti-insulin receptor antibody inhibits binding of insulin to insulin receptor and severe 
insulin resistance results. Type B insulin resistance usually associates with systemic lupus 
erythematosus (SLE) or Sjögren syndrome (SjS). In United States, Patients are usually 
African American women with hyperandorogenism and acanthosis nigricans. To control 
abnormal autoantibody, predonisolone (PSL), cyclophosphamide, cyclosporine A, 
azathiopurine, methotrexate, plasmapheresis, mycophenolate mofetil and rituximab are 
used with various effects. In some cases, hypoglycemia follows after severe hyperglycemia 
is ameliorated with various therapies. Occasionally, the anti-insulin receptor antibody has 
partial agonist activity and hypoglycemia is the first symptom. We have experienced a case 
of hypoglycemia complicated with type B insulin resistance and polymyositis. We reviewed 
case reports of type B insulin resistance from Japan. The Japanese patients with type B 
insulin resistance are usually not obese and more men than women were found. 
Hypoglycemia was observed relatively frequently. Complication with SLE was common, 
however a rare case complicated with Helicobacter pyroli infection was also reported.  
2. Case presentation 
In Augst 2009, a 54-year-old man admitted to the hospital for muscle pain and weakness. 
One month before admission, he noticed edema on both feet and swelling of his fingers of 
both hands. He had no pain however the hotness of the fingers disturbed sleeping. Ten days 
before admission, he had difficulty in moving his fingers because of the edema and he had 
pain on the palmar side of his hands. Then, swelling of both thighs and muscle pain of both 
shoulders had developed. He found weakness of the legs but could still walk on the stairs. His 
family doctor found elevation of creatin kinase (1580 mU/ml) and thrombocytopenia (79000 
/μl) and he was referred to this hospital. On admission, his body height was 167.6 cm, body 
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weight was 69.6kg and the body mass index (BMI) was 24.0 kg/m2. Pitting edema on lower 
legs and feet was found. His grasping power was difficult to measure because of the 
swelling of his fingers. However no apparent muscle weakness was observed by manual 
muscle testing. On his skin, no Gottron’s sign or Heliotrope rash was observed. He had 
muscle pain in the thigh. He had history of left VIIth nerve palsy when he was 40. VIIth 
nerve palsy recurred on the right side in April and then he was diagnosed as diabetes 
mellitus. He smoked one pack of cigarette and drinks a can of beer every day. His mother 
had diabetes and otherwise no particular family history was noticed. The results of the 
laboratory tests are listed in Table 1. 
 
     
WBC 
Hb 
Ht 
Platelet 
AST 
ALT 
LDH 
CK 
CK-MM 
CK-MB 
HbA1c 
Blood glucose after  
75 g oral glucose 
0 min 
60 min 
120 min 
Plasma insulin after 
75 g oral glucose  
0 min 
60 min 
120 min 
6970 /μl 
12.5 g/dl 
38.7% 
167000/μl 
163 mU/ml 
91 mU/ml 
523 mU/ml 
3296 mU/ml
97% 
3% 
6.6% 
 
 
54 mg/dl 
186 mg/dl 
249 mg/dl 
 
 
10 μU/ml 
517μU/ml 
981μU/ml 
C3 
C4 
D-dimer 
Anti-Jo-1 antibody 
Anti-RNP antibody 
Anti-nuclear antibody 
Anti-Scl-70 antibody 
Anti-SSA antibody 
Anti-SSB antibody 
Anti-mitochondria M2 antibody
KL-6 
SP-D 
SAA 
CRP 
CEA 
CA19-9 
Anti-insulin antibody 
Anti-insulin receptor antibody
electromyogram 
 
 
 
53 mg/dl (65-135) 
11 mg/dl 
2.9 μg/ml 
2 
Negative 
80 (diffuse, nuclear) 
Negative 
16 
Negative 
12 
331 U/ml 
31.8 ng/ml 
10.8 μg/ml 
0.35 mg/dl 
3.1 ng/ml 
3.3 U/ml 
Negative 
Inhibition rate 41% 
Low & short NMU in 
biceps, brachioradial, 
quadriceps femoris 
and tibialis anterior 
muscles 
Table 1. Laboratory data of the case NMU: neuromuscular unit 
He presented symptoms of fasting hypoglycemia and his fasting plasma glucose showed 
values between 50 and 70mg/dl repeatedly. His fasting plasma immunoreactive insulin 
(IRI) level was 21.2 μU/ml and was inappropriately high when the plasma glucose was 
62mg/dl. At two hours after breakfast, his plasma glucose was 139mg/dl and the IRI at this 
time point was 379 μU/ml. The HbA1c at admission was 6.6%. To confirm diagnosis, 75 g 
oral glucose tolerance test was performed. The blood glucose level after 2 hours was 249 
mg/dl. The IRI and C-peptide levels 2 hours after load were 981 μU/ml and 12.5 ng/ml 
respectively. Anti-insulin antibody was negative. Anti-insulin receptor antibody was 
present and the inhibition rate was 41%. During the course, serum creatine kinase level 
increased to over 7000 mU/ml and AST and ALT also moderately increased over 300 
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mU/ml. The antinuclear antibody, anti-SSA antibody and the Jo-1 antibody were positive, 
but not for anti-Scl70 or anti-SSB antibodies. Anti-mitochondria M2 antibody was also 
positive. The electromyogram was compatible with myopathy. A diagnosis of polymyositis 
complicated with type B insulin resistance was given. After that he was re-evaluated by a 
dermatologist for the presence of acanthosis nigricans and mild lesions were found in the 
axilla and the periumbilical region. Predonisolone therapy was started from 60 mg/day. The 
fasting plasma glucose increased to 198mg/dl and the plasma insulin level was 1399 μU/ml. 
To control the hyperglycemia, insulin therapy was started from 2 units of ultra-rapid insulin 
before each meal, then increased to 15 U/day. Severe hyperglycemia was ameliorated 
within one week and insulin therapy was stopped because fasting hypoglycemia recurred. 
Fasting hypoglycemia occurred repeatedly after discontinuation of insulin therapy but was 
manageable by oral glucose intake. The clinical course is presented in Figure 1. 
 
 
Fig. 1. Clinical course of the case 
The creatine kinase and AST responded gradually, however the response was slow and 
methotrexate 10 mg/week was added to prednisolone therapy. After one month 
predonisolone was tapered to 50mg/day then 40mg/dl three weeks later. Thereafter tapering 
schedule was slowed to 2.5mg/day every two weeks. The creatine kinase level decreased to 
upper normal limit at two months after admission. The HbA1c at this time point was 6.0%.  
Type B insulin resistance syndrome in Japan compared with that in the United States (US) 
have some differences. 
Our case was positive for anti-insulin receptor antibody however his insulin resistance was 
weak and hyperglycemia after PSL therapy was easily controlled by short term insulin 
therapy. Relatively low inhibition rate of insulin binding (41%) may be the cause of this 
observation. The difference of clinical course compared with the typical case in US may be 
related to ethnicity. Therefore we screened case reports on type B insulin resistance in Japan 
(Table 2). 
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No Age sex AN BMI Underlying 
disease 
Hypoglycemia OHA or insulin 
usage before 
hypoglycemia 
Reference 
1 54 M Yes 24 polymyositis Yes No This case 
2 47 F NR NR SLE No  Takeda 
3 48 F NR NR 
SLE, 
depression 
No  Sakai1 
4 50 F Yes NR SLE Yes Yes (IGF-1) Yamasaki 
5 59 M NR 16 SLE Yes No Kawashiri 
6 55 M NR NR SLE(possible) Yes No Gojo 
7 57 M NR NR SLE Yes Yes Ogata 
8 56 M No 22.7 SLE Yes No 
Sato, 
Shigihara 
9 23 F Yes 20.4 SLE Yes No Nagayama 
10 61 F NR NR SjS No  Ito 
11 72 F No 21.2 SjS No  Furukawa 
12 44 F Yes 
Not 
obese
SjS,  
Hashimoto 
No  Hirano 
13 60 M NR NR RA Yes No Tokumori 
14 67 M NR NR UCTD Yes No Yamagata 
15 59 M NR NR 
CH(C),  
PEG-IFN+ 
ribavirin 
No  Miyamoto 
16 74 M Yes 18.4 IPMT No  Uehara 
17 48 F Yes 19 T2DM only Yes Yes Sakai2 
18 68 M NR 22.6 AP No  Tashiro 
19 
84 M No 23 ITP,  Yes No Imai 
86  NR NR ITP Yes No Yamamiya 
AN: acanthosis nigricans, BMI: body mass inex (kg/m2), SLE: systemic lupus erythematosus, SjS: 
Sjögren’s syndrome, RA: rheumatoid arthritis, UCTD: undifferentiated collagen tissue disease, CH(C): 
chronic hepatitis virus C infection, PEG-IFN: pegylated interferon, IPMT: intrapancreatic duct 
mucinous tumor, AP: angina pectoris, ITP: idiopathic thrombocytopenic purpura, IGF-1: insulin-like 
growth factor-1, NR: not reported 
 
Table 2. Patients’ profiles of type B insulin resistance in Japan 
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No HbA1c 
(%) 
Insulin dose
(U/day) 
FPG 
(mg/dl) 
IRI 
(U/ml) 
CPR 
(ng/ml) 
PSL dose 
(mg/day) 
Other treatments 
1 6.0 15 62 21.2  60 MTX 
2 13.4 80 NR NR NR 50 IGF-1, CyA, 
rituximab 
3 NR 340  NR NR 25 CyA 200mg/day, 
rituximab 500mg 
x2 
4 NR 610 220 821 3.7 nM 30 IGF-1 
5 9.5 68 67 316 3.08 30 Plasma exchange 
immunoadsorptio
n 
CPA, CyA, IGF-1 
6 NR - NR NR NR NR Bed time snack 
7 NR >300 NR NR # >450 Pulse Plasma exchange 
8 9.1 - 38 697.7 14.2 60 - 
9 NR - 116 2313 55 mPSL 0.5g 
x2 
PSL 30 
- 
10 NR NR NR NR NR 50 IGF-1 
11 11.1 160 NR 462 5.1 - IGF-1 
12 NR 300 131 699.5 NR 40 IGF-1 
13 6.3 - 48 581 0.42 40 - 
14 NR NR NR NR NR 50 H.p. eradication 
15 NR NR NR NR NR NR - 
16 13.8 138 NR NR #138.4   
17 11.2 >200 180 490 6.52 - - 
111 NR 6.52 
66 15.9 0.7 
18 8.5 -(OHA) NR >1000 NR 2.5 - 
19 5.0 - 56 NR NR - H.p. eradication 
 - NR NR NR 20  
FPG: fasting plasma glucose, IRI: immunoreactive insulin, CPR: C-peptide reactivity, PSL: predonisolone, 
mPSL: methyl predonisolone, MTX: methotrexate, IGF-1: insulin-like growth factor-1, CyA: cyclosporine 
A, CPA: cyclophosphamide, #: urinary excretion of C-peptide (μg/day), H.p.: Helicobactor pyroli, OHA: 
oral hypoglycemic agent 
Table 3. Treatments of type B insulin resistance in Japan 
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In US, the majority of patients with type B insulin resistance are African American woman. 
Hyperandorogenism and acanthosis nigricans are common. Severe insulin resistance is the 
predominant symptoms and fasting or reactive hypoglycemia may follow after 
hyperglycemia is ameliorated by various treatments. Among reports on Japanese patients 
with type B insulin resistance, we found more men (11) than women (8). The description of 
acanthosis nigricans was not common. Among 9 cases with available report, 6 had 
acanthosis nigricans and 3 had not. Severe obesity was also rare. In the 24 cases of type B 
insulin resistance reported by Arioglu et al. three cases presented hypoglycemia after 
prolonged hyperglycemia (Arioglu 2002). Among the 19 cases in Japan, 11 cases had 
hypoglycemia somewhere during the course. Eight of these 11 cases were not using oral 
hypoglycemic agent or insulin when hypoglycemia was first noticed. Examples are briefly 
introduced below. 
A 23-year-old Japanese woman with SLE and on hemodialysis developed severe general 
fatigue (Nagayama et al. 2008). Her fasting blood glucose was between 25 to 45mg/dl. Her 
serum insulin level was 2313.8 μU/ml and anti-insulin receptor antibody was positive by 
125I –insulin binding inhibition assay. She also presented with acanthosis nigricans. Her 
hypoglycemia was restored after steroid pulse followed by high dose steroid therapy. 
A 56-year-old Japanese man was admitted to the hospital because of unconsciousness and 
hypoglycemia (Sato 2010). Anti-insulin antibody was positive. Episodes of hypoglycemia 
and hyperglycemia repeated despite predonisolone therapy (5-10 mg/day) Laboratory test 
revealed pancytopenia, positive antinuclear antibody and mild proteinuria. He also 
presented persistent discoid lesion of the skin. Renal biopsy was consistent with lupus 
nephritis. He was diagnosed as SLE and the dose of predonisolone was increased to 60 
mg/day. After that his blood glucose improved along with proteinuria. The dose of 
predonisolone could be successfully tapered to 30 mg/day. 
3. Underlying disease 
Type B insulin resistance associates most frequently with SLE and related connective tissue 
diseases. Sjögren’s syndrome and rheumatoid arthritis were also found. On the other hand, 
what is the prevalence of anti-insulin receptor antibody in SLE patients? Rosenstein et al. 
analyzed consecutive 38 patients with SLE or undifferentiated connective tissue disease 
(UCTD) for anti-insulin receptor antibody (Rosenstein et al. 2001). Within 26 SLE patients 
one was positive for anti-insulin receptor antibody and none in the 12 UCTD patients. None 
of their patients presented insulin resistance syndrome. In our case, polymyositis was the 
underlying disease. We searched PubMed for “polymyositis” and “insulin resistance” and 
found several reports on juvenile dermatomyositis (JDA) associated with lipodystrophy. In 
a report from Canada, 4 of 20 patients with JDA had lipodystrophy and severe insulin 
resistance (Huemer 2001). However anti-insulin receptor antibody was not detected by 
radioimmunoassay in these cases. Their pathophysiology was explained in the context of 
lipodystrophy. Lipodystrophy associated with dermatomyositis is not confined to pediatric 
patients. A case of 55-year-old woman with dermatomyositis complicated with 
lipodystrophy is reported (Lee and Hobbs). She developed hypertriglyceridemia 3 years 
after diagnosis of dermatomyositis and then lipodystrophy in the thigh appeared. Severe 
insulin resistance was not reported in this case. Our case did not have typical skin lesions 
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suggestive of dermatomyositis nor lipodystrophy. Therefore our case is not categorized in 
these insulin resistance associated with dermatomyositis. There are also reports of type B 
insulin resistance associated with interferon-alpha treatment (Miyamoto). Unfortunately, the 
detail of this case was not described in the literature. A similar case is reported by Daniel et 
al. A 55-year-old African American man with hepatitis C developed severe hyperglycemia 
eight months after treatment with interferon-alpha and ribavirin. He needed up to 125 U/hr 
of insulin and anti-insulin receptor antibody was detected in his serum. After 
discontinuation of interferon-alpha and ribavirin, his insulin resistance resolved 
spontaneously. Type B insulin resistance associated with idiopathic thrombocytopenic 
purpura (ITP) is also reported. Helicobactor pyroli infection is one of the causes of ITP and 
eradication of H. pyroli by proton pump inhibitor and antibiotics may relieve the 
thrombocytopenia. In Japan a case of type B insulin resistance that was ameliorated after 
eradication of H. pyroli has been reported (Imai). Interestingly, three years after the first 
episode, hypoglycemia recurred in this patient (Yamamiya). This time his plasma insulin 
was below detection limit when he was hypoglycemic. Anti-insulin receptor antibody was 
not proved by 125I-insulin binding inhibition assay. Unfortunately, other method to detect 
anti-insulin receptor antibody has not been performed. Imunoprecipitation of insulin 
receptor by the patient’s serum may probe anti-insulin receptor antibody. The change of the 
epitope of the anti-insulin receptor antibody may result in agonistic activity without 
inhibiting insulin binding. 
4. Treatment of abnormal glucose metabolism 
The dose of insulin utilized to control hyperglycemia was substantially small compared 
with that in the US (Arioglu, Lupsa, Malek). The Japanese patients with type B insulin 
resistance were treated no more than several hundred units a day. In the cases reported by 
Arioglu, on average 5100 U/day was used. A case with type B insulin resistance and SLE 
reported by Bao et al. required up to 4500 U/day insulin to control hyperglycemia. She was 
treated with azathiopurine for 3 months. Another severe insulin resistance case reported by 
Ostwal et al. required up to 2800 U/day. She had SLE and anti-insulin receptor antibody 
was probed by immunoprecipitation assay. A steroid pulse therapy with 
mehylpredonisolone 1 g for 3 days was performed followed by maintenance dose of steroid 
and azathiopurine. Her insulin requirement decreased gradually and stopped. After that she 
required 3-hourly meals to avoid hypoglycemia. In the treatment of hyperglycemia, insulin 
like growth factor-I (IGF-I, Astellas Pharmaceutical Co. Ltd. Tokyo) injection was tried in 
several Japanese patients with varying effectiveness. The anti-insulin receptor antibody does 
not necessarily affect insulin-like growth factor receptor. Therefore IGF-1 injection is worth 
trying if there are no contraindications such as proliferative retinopathy or malignancy. 
Type B insulin resistance is potentially a self-limited disease. However to treat severe 
hyperglycemia in a certain time frame may require immunosuppressive medications and/or 
plasma exchange. In our patient, severe hyperglycemia developed only after initiation of 
predonisolone therapy. His hyperglycemia was controlled with relatively small dose of 
insulin in a short time and hypoglycemia repeated after discontinuation of insulin therapy. 
This may reflect the agonistic character of anti-insulin receptor antibody in his case. Because 
predonisolone is frequently used to treat underlying disease, hypoglycemia is relatively 
easy to control although timed snack may be required to avoid fasting hypoglycemia. 
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5. Treatment of autoimmunity 
Attempt to control abnormal autoantibody is mainly through control over underlying 
disease. Because SLE is the most predominant underlying disease, predonisolone therapy 
with or without pulse therapy is most commonly attempted. Methotrexate, azathiopurine, 
cyclophosphamide and mycophenolate mofetil are also used in resistant cases. 
Plasmapheresis or immunoadsorption is used in some cases to remove anti-insulin receptor 
antibody in a short time. Recently rituximab is another choice to reduce B-cells producing 
autoantibodies. Because the case of type B insulin resistance is rare, randomized control 
study is difficult to perform. Therefore the comparison of effectiveness of these various 
therapies is difficult. The choice of treatment seems to be determined by the familiarity of 
the doctors to each treatment. Also the anti-insulin receptor antibody may disappear 
spontaneously at least in some cases. This complicates the analysis of result. Therefore it 
seems to be prudent to choose treatment based on the effectiveness to control the underlying 
disease. 
6. Prognosis 
Arioglu reported that the prognosis of type B insulin resistance may be poor especially in 
those with hypoglycemia. Among the 19 cases at least two was reported as deceased. One of 
the two, a 23 year-old woman was on hemodialysis complicated with SLE when her 
hypoglycemia developed. She had intractable lung infection during the treatment of 
exacerbated SLE. Another case, a 56 year-old man with severe SLE died of sepsis. 
Hypoglycemia was not the direct cause of death for these cases. We have no data for other 
cases.  
7. Characterization of anti-insulin receptor antibody 
The presence of anti-insulin receptor antibody is probed with various methods. Inhibition of 
binding of 125I-labelled insulin to insulin receptor is the method commonly used by 
commercial laboratory in Japan. The result is reported as inhibition rate. One problem of 
binding inhibition is that we cannot know whether the anti-insulin receptor antibody has 
agonist activity to insulin receptor. Another problem is that insulin binding is interfered by 
anti-insulin antibody if it coexists. This is a rare occasion however there are several cases in 
whom both anti-insulin antibody and anti-insulin receptor antibody were probed. The anti-
insulin receptor is polyclonal and the character of the antibody may change during the 
course. Yamasaki et al. analyzed the insulin-like activity of the patient’s serum during the 
course from severe hyperglycemia to fasting hypoglycemia. At first, her hyperglycemia was 
resistant to insulin at maximum 610 μU/day. After treatment with PSL, fasting 
hypoglycemia occurred. The activity to stimulate 2-deoxyglucose uptake was most 
prominent in the serum during the hyperglycemic phase and the serum during the 
hypoglycemic phase showed weaker activity. The activity to stimulate insulin receptor 
autophosphorylation was also most strong in the serum during the hyperglycemic phase. 
Their data suggest that antibody with agonistic activity may also present in patients who 
show no hypoglycemia. Receptor down regulation caused by autoantibody may modify the 
patient’s response.  
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8. Epitopes of the autoantibodies 
The extracellular part of the insulin receptor is composed of leucine rich domain 1, 
cysteine rich domain, leucine rich domain 2 and three fibronectin type III domains 
(McKern). Analysis using chimeric receptor has provided clue to the epitope of the anti-
insulin receptor antibodies. Chimeric IGF-I receptor containing residues 450-601 of the 
insulin receptor was recognized by 12 of 15 sera from type B insulin resistance (Zhang & 
Roth). Residues 471-593 is the first fibronectin type III domain and monoclonal antibody 
to this region can inhibit high affinity insulin binding (Surinya). The epitopes of anti-
insulin receptor antibody were analyzed by recognition of peptides from human insulin 
receptor expressed in bacteria (Pritgent 1990). A monoclonal antibody (83-14) mimics 
insulin action and inhibits insulin binding. This antibody recognizes amino acids 469-592. 
Another monoclonal antibody (18-44) also mimics insulin action but does not inhibit 
insulin binding. This antibody recognizes amino acids 765-770 within the third fibronectin 
type III domain in the N-terminus of the beta subunit. Chrystallographic study of the 
ectodomain of human insulin receptor revealed that the insulin binding pocket is made of 
N-terminal leucine rich repeat and the first fibronectin type III domain (McKern). The 
third fibronectin type III domain is outside the insulin binding pocket. Therefore if 
antibody to amino acids 765-770 is predominant, hypoglycemia without insulin resistance 
will result. In such a case, anti-insulin receptor antibody cannot be proved by binding 
inhibition assay. In the case reported by Yamamiya, anti-insulin receptor antibody was 
not detected by insulin binding inhibition when hypoglycemia recurred. This may result 
from change in the epitopes of the autoantibody. We should recall the possibility of anti-
insulin receptor antibody when we see hypoglycemia associated with very low insulin 
level.   
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